A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy-Reference-Cited by-同舟云学术

A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy

Published:2022-07 Issue: Volume:63 Page:103860
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Kozlicki Miranda Z.,Markley Brandon,Shah Nisha B.,DeClercq Josh,Choi Leena,Zuckerman Autumn D.

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference27 articles.

1. Ford CC, Morrow SA. CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis 2019:1–47.

2. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence–Terminology and definitions. Value Health. 2008;11:44–47.

3. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis;Thomas;J. Med. Econ.,2016

4. Real-World adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year;Johnson;J. Manag. Care Spec. Pharm.,2017

5. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis–A population-based study;Setayeshgar;Mult. Scler. Relat. Disord.,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-08

2. Real‐world persistence of multiple sclerosis disease‐modifying therapies;European Journal of Neurology;2024-04-03

3. Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis;Journal of Managed Care & Specialty Pharmacy;2024-04

4. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study;Multiple Sclerosis and Related Disorders;2023-11

5. Patient-reported outcomes and pharmacist actions in patients with multiple sclerosis managed by health-system specialty pharmacies;American Journal of Health-System Pharmacy;2023-08-09